Q / What is the best treatment for impetigo?
A / ALTHOUGH EVIDENCE IS LACKINGING to support a single best treatment for impetigo, topical mupirocin, fusidic acid, gentamicin, and retapamulin are all at least 20% more likely than placebo to produce cure or improvement (strength of recommendation [SOR]: A, meta-analysis of randomized controlled trials [RCTs] and a single RCT of retapamulin).
Topical bacitracin and fusidic acid are 15% more likely than disinfectant solutions to cure or improve impetigo (SOR: A, systematic review of RCTs).
Oral antibiotics may be as effective as topical antibiotics (SOR: B, RCTs with different results).
Most data on the effectiveness of topical antibiotics focus on bacitracin, fusidic acid (not available in the United States), and mupirocin. Retapamulin 1% ointment, a topical antibiotic in the pleuromutilin class, is approved by the US Food and Drug Administration (FDA) for use in adults and children older than 9 months to treat impetigo caused by methicillin-susceptible Staphylococcus aureus and Streptococcus pyogenes. (1)
Topical antibiotics outperform placebo
A 2003 meta-analysis of 16 studies (1944 patients) evaluated treatments for impetigo in both adults and children. (2) Investigators conducted most of the studies in outpatient settings in the United States, United Kingdom, Northern Europe, and Canada. They expressed outcomes in terms of cure or clinical improvement within 7 to 14 days of starting treatment.
Topical agents, including mupirocin, fusidic acid, and gentamicin, resulted in cure or improvement in more patients at 7 to 14 days than placebo (absolute benefit increase=20%; number needed to treat [NNT]=5; 95% confidence interval [CI], 1.49-4.86). Definitions of cure or improvement varied among the included studies, however.
A 2012 Cochrane review of various interventions included 68 RCTs with a total of 5708 participants, primarily from pediatric or dermatology hospital outpatient clinics in North America and Europe. (3) Clinical cure (defined as clearance of crusts, blisters, and redness as determined by investigators) or improvement at one week were the primary outcomes (TABLE). (3,4) Mupirocin (relative risk [RR]=2.21; 95% CI, 1.16-3.13), fusidic acid (RR=4.42; 95% CI, 2.39-8.17), and retapamulin (RR=1.64; 95% CI, 1.30-2.07) all demonstrated higher rates of cure or improvement than placebo.
Retapamulin produces greater clinical response than placebo in an RCT
A 2008 randomized, double-blind, multicenter, industry-funded, placebo-controlled trial of 213 patients evaluated the effectiveness of retapamulin to treat uncomplicated impetigo with an outcome of clinical response at 7 days. (4) Clinical response was defined as total absence of lesions, drying of treated lesions without crusts or erythema, decrease in the size of the affected area or decrease in the number of lesions. Retapamulin ointment produced a higher rate of clinical response than placebo (absolute risk reduction=33.5%; 95% CI, 20.5-46.5; NNT=3, P <. 001).
Topical antibiotics work slightly better than disinfectant solutions
In a pooled analysis from the 2012 Cochrane review, topical bacitracin and fusidic acid demonstrated slightly higher rates of cure or improvement than disinfectant solutions (RR=1.15; 95% CI, 1.01-1.32). (3)
Oral antibiotics may work as well as, or better than, topicals
The 2012 Cochrane review found better rates of cure or improvement for topical mupirocin than oral erythromycin (RR=1.07; 95% CI, 1.01-1.13). (3) Investigators noted no significant differences between topical mupirocin and bacitracin and oral antibiotics other than erythromycin, although in one small study (10 patients), oral cephalexin resulted in a higher rate of cure or improvement than topical bacitracin (absolute risk reduction [ARR]=56.7%; NNT=2).
Studies comparing oral antibiotics found that both erythromycin and cloxacillin (not available in the United States) produced higher rates of cure or improvement than penicillin (erythromycin, RR=1.29; 95% CI, 1.07-1.56; cloxacillin, RR=1.14; 95% CI, 0.80-1.62).
The Infectious Diseases Society of America recommends topical mupirocin as first-line therapy for impetigo, although resistance to the drug exists. Patients with numerous lesions or who fail to respond to topical treatment should be treated with oral antibiotics active against S pyogenes and S aureus. Recommended oral antibiotics include dicloxacillin, amoxicillin/clavulanate, cephalexin, erythromycin, and clindamycin.
(1.) Altabax. Med Library Web site. Available at: http://medlibrary.org/ lib/rx/meds/altabax-3/. Accessed May 12,2014.
(2.) George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. Br J Gen Practice. 2003;53:480-487.
(3.) Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;1:CD003261.
(4.) Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158:1077-1082.
(5.) Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406.
Jae Shim, MD; Jeffrey Lanier, MD
Martin Army Community Hospital, Fort Benning, Ga
Maylene (Kefeng) Qui, MLIS
Biomedical Library, University of Pennsylvania, Philadelphia
Paul Crawford, MD
Nellis Family Medicine Residency, Nellis Air Force Base, Nev
The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Army or the Department of Defense.
TABLE How well do impetigo treatments work? (3,4) Comparison Number of ARR for NNT Cost of patients cure or treatment * improvement Topical 575 41.2% 2 antibiotics vs placebo Retapamulin 213 33.5% 3 Retapamulin vs placebo 1 % ointment (15 g): $130.12 Topical 292 11.4% 9 antibiotics vs disinfectant solution Mupirocin 440 NS NS Mupirocin vs fusidic ointment acid 2% (22 g): $42.75 Fusidic acid is not available in the United States Mupirocin 581 5.1% 20 Erythromycin vs oral 100 tabs: erythromycin $295.01 (250 mg), $314.23 (333 mg), $338.93 (500 mg) Erythromycin ethylsuccinate solution (100 mL): $170.50 (200 mg/5 mL), $218.14(400 mg/5 mL) Mupirocin 53 NS NS Dicloxacillin vs 100 tabs dicloxacillin (250 mg): $66 Mupirocin 13 NS NS Ampicillin vs 100 tabs ampicillin (500 mg): $39.88 Ampicillin suspension 100 mL: $9.54 (125 mg/5 mL), $14.08 (250 mg/5 mL) Bacitracin 30 NS NS Bacitracin vs oral ointment erythromycin 500 units/ g (28.4 g): $3.47 Bacitracin 34 NS NS Penicillin vs V oral 100 penicillin tabs (500 mg): $77.77 Penicillin V suspension 100 mL: $3.84 (125 mg/5 mL), $4.31 (250 mg/5 mL) Cephalexin 19 56.7% 2 Cephalexin vs 100 tabs bacitracin (500 mg): $526.13 Cephalexin oral suspension 100 mL: $8.93 (125 mg/5 mL), $18.90 (250 mg/5 mL) Erythromycin 79 22.4% 4 See above vs penicillin Cloxacillin 166 35.9% 3 Cloxacillin vs is not penicillin available in the United States ARR, absolute risk reduction; NNT, number needed to treat; NS, not significant. Cost data obtained from Medi-Span at www.uptodate.com. Accessed December 5, 2013.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CLINICAL INQUIRIES: Evidence-based answers from the family Physicians Inquiries Network|
|Author:||Shim, Jae; Lanier, Jeffrey; Qui, Maylene "Kefeng"|
|Publication:||Journal of Family Practice|
|Article Type:||Clinical report|
|Date:||Jun 1, 2014|
|Previous Article:||Teenager with shortness of breath and hypoxia: in addition to the signs and symptoms that brought this teen to our ED, there was one important detail...|
|Next Article:||Q / Do complementary agents lower HbA1c when used with standard type 2 diabetes therapy?|